Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC oxaliplatin + raltitrexed versus sorafenib for intermediate- and advanced-stage hepatocellular carcinoma
ChiCTR2000032992Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing HAIC oxaliplatin + raltitrexed with Oral sorafenib (2 arms). Primary endpoints: Tumor response and Overall survival. Planned start May 2020; status: not yet recruiting.
02
Drugs
oxaliplatinraltitrexedsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000032992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032992.